View More Recent Stories

May 2, 2025 07:12AM Agios Pharma (AGIO) PT Lowered to $71 at Scotiabank
May 1, 2025 06:31AM Agios Pharma (AGIO) Tops Q1 EPS by 23c
Apr 12, 2025 04:00AM Biotech sector Q1 earnings preview from RBC Capital Markets
Apr 2, 2025 07:04AM Smid cap biotech investors must stop chasing binary events says Cantor Fitzgerald
Mar 5, 2025 05:58PM Agios Pharma (AGIO) announces inducement grants to new CPO
Feb 24, 2025 06:21AM H.C. Wainwright Starts Agios Pharma (AGIO) at Buy
Feb 21, 2025 06:13AM Agios Pharma (AGIO) BofA Makes Changes to Endeavor List
Feb 13, 2025 06:32AM Agios Pharma (AGIO) reported revenue at $10.7 million
Feb 13, 2025 06:30AM Agios Pharma (AGIO) Reports Phase 3 ACTIVATE-Kids Study of Mitapivat Met Primary Endpoint
Jan 13, 2025 12:50PM RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
Jan 8, 2025 07:02AM Agios Pharma (AGIO) Announces FDA Acceptance of sNDA for PYRUKYND
Dec 21, 2024 10:00AM RBC report: Biotech faces both uncertainty and growth opportunities in 2025
Dec 18, 2024 07:04AM Agios Pharma (AGIO): European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease
Dec 10, 2024 07:28AM Agios Pharma (AGIO) PT Raised to $57 at RBC Capital; 'We Are Continued Buyers'
Dec 9, 2024 03:30PM Agios Pharma (AGIO) puts active as share price down 22%
Oct 31, 2024 01:17PM Raymond James Reiterates Outperform Rating on Agios Pharma (AGIO)
Oct 31, 2024 06:32AM Agios Pharma (AGIO) Tops Q3 EPS by $1
Oct 23, 2024 07:07AM Agios Pharma (AGIO) Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease
Oct 15, 2024 05:59AM Leerink Partners Reiterates Market Perform Rating on Agios Pharma (AGIO)
Oct 10, 2024 08:19AM Raymond James Resumes Agios Pharma (AGIO) at Outperform
Sep 27, 2024 06:37AM Leerink Partners Downgrades Agios Pharma (AGIO) to Market Perform
Sep 26, 2024 07:15AM Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)
Sep 24, 2024 02:51PM Agios Pharma (AGIO) 2K contracts of December 40 puts trade at $1.35
Sep 11, 2024 07:00AM Agios Pharma (AGIO) Receives FDA Orphan Drug Designation for Tebapivat
Sep 10, 2024 07:22AM Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)
Aug 2, 2024 06:21AM Agios Pharma (AGIO) PT Raised to $55 at RBC Capital
Aug 1, 2024 06:37AM Agios Pharma (AGIO) Misses Q2 EPS by 9c
Aug 1, 2024 06:31AM Agios Pharma (AGIO) Reports Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat
Jul 30, 2024 07:17AM RBC's biotech survey shows investors more bearish vs. last time
Jul 9, 2024 07:00PM 2Q24 U.S. biotech earnings preview
Jun 17, 2024 10:07AM TD Cowen Reiterates Buy Rating on Agios Pharma (AGIO)
Jun 17, 2024 07:54AM Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)
Jun 13, 2024 04:55PM JPMorgan Resumes Agios Pharma (AGIO) at Neutral
View More Recent Stories